Evidence map›Paper›PMID 39952701›Full record

ArticleMethods in enzymology2025

cP-RNA-seq for tRNA half sequencing.

Megumi Shigematsu, Justin Gumas, Yohei Kirino

Abstract read
In one paragraph

Article in Methods in enzymology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Megumi ShigematsuComputational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States.
Justin GumasComputational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States.
Yohei KirinoComputational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States. Electronic address: Yohei.Kirino@jefferson.edu.

Funding

piRNA biogenesis ruled by PIWI-TUDOR interactionR01GM106047 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI KIRINO, YOHEI · 2013 to 2022
$2.8M
tRNA-derived non-coding RNAs in ASM function and in asthmaR01HL150560 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI DESHPANDE, DEEPAK A, KIRINO, YOHEI · 2020 to 2023
$2.4M
Role of tRNA- and rRNA-derived RNAs in acute lung injuryR01HL175371 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI Deepak A Deshpande, Yohei Kirino · 2024 to 2026
$1.9M
Biogenesis and function of cyclic phosphate-containing RNAsR35GM156496 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI Yohei Kirino · 2025 to 2026
$858k
Role of Toll-like receptor-induced short non-coding RNAs in innate immune responseR21AI151641 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI KIRINO, YOHEI · 2021 to 2022
$429k
Role of rRNA-derived short non-coding RNAs in innate immune responseR21AI168975 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI KIRINO, YOHEI · 2022 to 2023
$429k
Endogenous single-stranded RNA ligands for endosomal Toll-like receptorsR21AI171366 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI KIRINO, YOHEI · 2023 to 2024
$429k
NHLBI NIH HHS R01 HL150560NHLBI NIH HHS R01 HL175371NIAID NIH HHS R21 AI151641NIAID NIH HHS R21 AI168975NIAID NIH HHS R21 AI171366NIGMS NIH HHS R01 GM106047NIGMS NIH HHS R35 GM156496
6 · The paper itself

Abstract

Although RNA-seq data are becoming more widely available for biomedical research, most datasets for short non-coding RNAs (sncRNAs) primarily focus on microRNA analysis using standard RNA-seq, which captures only sncRNAs with 5'-phosphate (5'-P) and 3'-hydroxyl (3'-OH) ends. Standard RNA-seq fails to sequence sncRNAs with different terminal phosphate states, including tRNA halves, the most abundant class of tRNA-derived sncRNAs that play diverse roles in various biological processes. tRNA halves are produced through the endoribonucleolytic cleavage of mature tRNA anticodon loops. The responsible endoribonucleases, such as Angiogenin, commonly leave a 2',3'-cyclic phosphate (cP) at the 3'-end of 5'-tRNA halves and forms a 5'-OH end of 3'-tRNA halves, making them incompatible with standard RNA-seq. We developed a method named "cP-RNA-seq" that selectively amplifies and sequences tRNA halves and other cP-containing sncRNAs. Here we describe a detailed and recently updated cP-RNA-seq protocol. In this method, the 3'-end of all sncRNAs, except those containing a cP, are cleaved through periodate treatment after phosphatase treatment. Consequently, adaptor ligation and cDNA amplification steps are exclusively applied to cP-containing sncRNAs. Our cP-RNA-seq only requires commercially available reagents and is broadly applicable for the global identification of tRNA halves and other cP-containing sncRNA repertoires in various transcriptomes.

Indexed as

RNA-SeqRNA, Small UntranslatedRNA, TransferSequence Analysis, RNAHumansRNA, Small UntranslatedRNA, Transfer2′,3′-cyclic phosphate (cP)cP-containing RNA (cP-RNA)cP-RNA-seqRNA-seqShort non-coding RNA (sncRNA)tRNA half

Identifiers

PMID39952701
PMCPMC11938272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.